NCT04688021 is a Phase 2 clinical trial of Cytarabine in Leukemia, sponsored by Yi Luo.

Who is sponsoring NCT04688021?

NCT04688021 is sponsored by Yi Luo.

What drugs are being tested in NCT04688021?

Interventions in NCT04688021: Cytarabine, Busulfan, Cyclophosphamide, Me-CCNU, Rabbit antithymocyte globulin, Tocilizumab, Allogeneic HSCT, Cyclosporin A, Mycophenolate Mofetil, MTX.

What condition does NCT04688021 study?

NCT04688021 studies Leukemia, Graft-versus-host-disease.

Is NCT04688021 still recruiting?

NCT04688021 is currently status unknown. Last updated 21 February 2023.

Last reviewed 2023-02-21 · How we verify

NCT04688021

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Single-arm Trial of Prophylactic Tocilizumab for Acute GVHD Prevention After Haploidentical HSCT.

Status unknown Phase 2 Last updated 21 February 2023

What this trial tests

Phase 2 trial testing Cytarabine in Leukemia in 46 participants. Status unknown.

Timeline

3 December 2020

Primary endpoint
3 December 2024

31 December 2024

Quick facts

Lead sponsor	Yi Luo
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	prevention
Enrollment	46
Start date	3 December 2020
Primary completion	3 December 2024
Estimated completion	31 December 2024
Sites	1 location across China

Drugs / interventions tested

Cytarabine — full drug profile →
Busulfan — full drug profile →
Cyclophosphamide (cyclophosphamide) — full drug profile →
Me-CCNU
Rabbit antithymocyte globulin
Tocilizumab (tocilizumab) — full drug profile →
Allogeneic HSCT
Cyclosporin A
Mycophenolate Mofetil (MYCOPHENOLATE MOFETIL) — full drug profile →
MTX

Conditions studied

Leukemia — all drugs for Leukemia →
Graft-versus-host-disease — all drugs for Graft-versus-host-disease →

Sponsor

Yi Luo — full company profile →

Who can join

Adults 16 to 60, any sex, with Leukemia or Graft-versus-host-disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A single-arm trial using Tocilizumab for acute GVHD prophylaxis after haploidentical HSCT.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Challenges and opportunities targeting mechanisms of epithelial injury and recovery in acute intestinal graft-versus-host disease.
Jansen SA, Nieuwenhuis EES, Hanash AM, Lindemans CA. · · 2022 · cited 24× · PMID 35654837 · DOI 10.1038/s41385-022-00527-6
Immunopathogenic mechanisms and modulatory approaches to graft-versus-host disease prevention in acute myeloid leukaemia.
Pang Y, Holtzman NG. · · 2023 · cited 3× · PMID 37353287 · DOI 10.1016/j.beha.2023.101475

Verify or expand the search:

Other trials of Cytarabine

Trials testing the same drug.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07498465 — A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant · Phase 1 · withdrawn
NCT07444710 — Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) · Phase 1 · not yet recruiting
NCT07428486 — A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractor · Phase 1 · not yet recruiting
NCT07022678 — Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia · Phase 3 · not yet recruiting

Other recruiting trials for Leukemia

Currently open trials in the same condition.

NCT07405424 — Spiritual Care Intervention in Adult Patients Diagnosed With Acute Leukemia · NA · recruiting
NCT07249346 — Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease ( · Phase 2 · recruiting
NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
NCT06856226 — Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing · recruiting
NCT07148180 — A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04688021 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yi Luo
Last refreshed: 21 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04688021.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing